Stephen D Hursting
Overview
Explore the profile of Stephen D Hursting including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
5195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giles E, Cook K, Jenschke R, Corleto K, Landrock D, Mahmood T, et al.
JCI Insight
. 2025 Mar;
PMID: 40048260
Many risk-eligible women refuse tamoxifen for primary prevention of breast cancer due to concerns about common side effects such as vasomotor symptoms. Tamoxifen may also induce or worsen insulin resistance...
2.
Devericks E, Brosnan B, Ho A, Glenny E, Malian H, Teegarden D, et al.
Cancer Metab
. 2025 Feb;
13(1):11.
PMID: 40001204
Introduction: Triple-negative breast cancer (TNBC), which tends to be more advanced when diagnosed and more aggressive than other breast cancer subtypes, is accelerated by obesity. Hypertrophic adipocytes and cancer cells...
3.
Andolino C, Cotul E, Xianyu Z, Li Y, Bhat D, Ayers M, et al.
Res Sq
. 2024 Dec;
PMID: 39678343
Lipid accumulation is associated with breast cancer metastasis. However, the mechanisms underlying how breast cancer cells increase lipid stores and their functional role in disease progression remain incompletely understood. Herein...
4.
Yum C, Andolino C, Layosa M, Coleman M, Hursting S, Teegarden D
Diabetol Metab Syndr
. 2024 Nov;
16(1):288.
PMID: 39609706
Background: Leptin, an energy balance regulator secreted by adipocytes, increases metastatic potential of breast cancer cells. The impact on cancer cell metabolism remains unclear given that most studies of leptin...
5.
Kong W, Deng B, Shen X, John C, Haag J, Sinha N, et al.
Gynecol Oncol
. 2024 Oct;
191:116-123.
PMID: 39388742
Objective: Interventions that combat obesity and its associated metabolic perturbations may decrease incidence and improve outcomes of endometrial cancer (EC). Potential options for weight loss include pharmacotherapeutic interventions such as...
6.
Carson M, Radler P, Albright J, VerHague M, Rezeli E, Roth D, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199576
Obesity is an established risk and progression factor for triple-negative breast cancer (TNBC), but preclinical studies to delineate the mechanisms underlying the obesity-TNBC link as well as strategies to break...
7.
Clontz A, Gan E, Hursting S, Bae-Jump V
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927903
Endometrial cancer (EC) includes various histologic types, with estrogen-dependent endometrioid carcinoma being the most common. Obesity significantly increases the risk of developing this type, especially in postmenopausal women, due to...
8.
Li Y, Madduri S, Rezeli E, Santos C, Freeman Iii H, Peng J, et al.
Front Nutr
. 2024 Jun;
11:1356038.
PMID: 38868554
Introduction: Obesity is a multi-factorial disease frequently associated with poor nutritional habits and linked to many detrimental health outcomes. Individuals with obesity are more likely to have increased levels of...
9.
Coleman M, Cotul E, Pfeil A, Devericks E, Safdar M, Monteiro M, et al.
Breast Cancer Res
. 2024 Jun;
26(1):96.
PMID: 38849928
Background: Metabolic plasticity mediates breast cancer survival, growth, and immune evasion during metastasis. However, how tumor cell metabolism is influenced by and feeds back to regulate breast cancer progression are...
10.
Ho A, Kiesel V, Gates C, Brosnan B, Connelly S, Glenny E, et al.
Cells
. 2024 May;
13(10).
PMID: 38786030
Triple-negative breast cancer (TNBC) lacks targeted therapies, leaving cytotoxic chemotherapy as the current standard treatment. However, chemotherapy resistance remains a major clinical challenge. Increased insulin-like growth factor 1 signaling can...